The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion
Open accessAbstract
Despite breakthroughs in immune checkpoint inhibitor (ICI) immunotherapy, not all human cancers respond to ICI immunotherapy and a large fraction of patients with the responsive types of cancers do not respond to current ICI immunotherapy. This clinical conundrum suggests that additional immune checkpoints exist. We report here that interferon regulatory factor 8 (IRF8) deficiency led to impairment of cytotoxic T lymphocyte (CTL) activation and allograft tumor tolerance. However, analysis of chimera mice with competitive reconstitution of WT and IRF8-KO bone marrow cells as well as mice with IRF8 deficiency only in T cells indicated that IRF8 plays no intrinsic role in CTL activation. Instead, IRF8 functioned as a repressor of osteopontin (OPN), the physiological ligand for CD44 on T cells, in CD11b+Ly6CloLy6G+ myeloid cells and OPN acted as a potent T cell suppressor. IRF8 bound to the Spp1 promoter to repress OPN expression in colon epithelial cells, and colon carcinoma exhibited decreased IRF8 and increased OPN expression. The elevated expression of OPN in human colon carcinoma was correlated with decreased patient survival. Our data indicate that myeloid and tumor cell-expressed OPN acts as an immune checkpoint to suppress T cell activation and confer host tumor immune tolerance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689
Fas and Perforin Pathways as Major Mechanisms of T Cell-Mediated Cytotoxicity
Kägi, D., Vignaux, F., Ledermann, B., Bürki, K., Depraetere, V., Nagata, S., Hengartner, H., & Golstein, P. (1994) · Science · doi:10.1126/science.7518614 · Cited by 1,516
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Boussiotis, V. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1514296 · Cited by 1,339
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018
Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
Kamphorst, A. O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D. L., Konieczny, B. T., Daugherty, C. Z., Koenig, L., Yu, K., et al. (2017) · Science · doi:10.1126/science.aaf0683 · Cited by 1,015
Juneja, V. R., McGuire, K. A., Manguso, R. T., LaFleur, M. W., Collins, N., Haining, W. N., Freeman, G. J., & Sharpe, A. H. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160801 · Cited by 851
Holtschke, T., Löhler, J., Kanno, Y., Fehr, T., Giese, N., Rosenbauer, F., Lou, J., Knobeloch, K.-P., Gabriele, L., Waring, J. F., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81348-3 · Cited by 644
Self-citationAdaptive Immune Resistance: How Cancer Protects from Immune Attack
Ribas, A. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0563 · Cited by 613
IRF8 Mutations and Human Dendritic-Cell Immunodeficiency
Hambleton, S., Salem, S., Bustamante, J., Bigley, V., Boisson-Dupuis, S., Azevedo, J., Fortin, A., Haniffa, M., Ceron-Gutierrez, L., Bacon, C. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100066 · Cited by 598
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
Lin, H., Wei, S., Hurt, E. M., Green, M. D., Zhao, L., Vatan, L., Szeliga, W., Herbst, R., Harms, P. W., Fecher, L. A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96113 · Cited by 584
PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
Tang, H., Liang, Y., Anders, R. A., Taube, J. M., Qiu, X., Mulgaonkar, A., Liu, X., Harrington, S. M., Guo, J., Xin, Y., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96061 · Cited by 524
Kao, C., Oestreich, K. J., Paley, M. A., Crawford, A., Angelosanto, J. M., Ali, M.-A. A., Intlekofer, A. M., Boss, J. M., Reiner, S. L., Weinmann, A. S., et al. (2011) · Nature Immunology · doi:10.1038/ni.2046 · Cited by 484
Antigen-driven effector CD8 T cell function regulated by T-bet
Sullivan, B. M., Juedes, A., Szabo, S. J., von Herrath, M., & Glimcher, L. H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2636938100 · Cited by 439
Agrawal, D. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.7.513 · Cited by 413
Grajales-Reyes, G. E., Iwata, A., Albring, J., Wu, X., Tussiwand, R., KC, W., Kretzer, N. M., Briseño, C. G., Durai, V., Bagadia, P., et al. (2015) · Nature Immunology · doi:10.1038/ni.3197 · Cited by 399
Eradication of Established Tumors by CD8+ T Cell Adoptive Immunotherapy
Hanson, H. L., Donermeyer, D. L., Ikeda, H., White, J. M., Shankaran, V., Old, L. J., Shiku, H., Schreiber, R. D., & Allen, P. M. (2000) · Immunity · doi:10.1016/s1074-7613(00)00026-1 · Cited by 358
Coppola, D., Szabo, M., Boulware, D., Muraca, P., Alsarraj, M., Chambers, A. F., & Yeatman, T. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1405-2 · Cited by 341
Sichien, D., Scott, C. L., Martens, L., Vanderkerken, M., Van Gassen, S., Plantinga, M., Joeris, T., De Prijck, S., Vanhoutte, L., Vanheerswynghels, M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.08.013 · Cited by 328
An early history of T cell-mediated cytotoxicity
Golstein, P., & Griffiths, G. M. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0009-3 · Cited by 284
Essential role of the IRF8-KLF4 transcription factor cascade in murine monocyte differentiation
Kurotaki, D., Osato, N., Nishiyama, A., Yamamoto, M., Ban, T., Sato, H., Nakabayashi, J., Umehara, M., Miyake, N., Matsumoto, N., et al. (2013) · Blood · doi:10.1182/blood-2012-06-437863 · Cited by 252
Self-citationLesley, J., He, Q., Miyake, K., Hamann, A., Hyman, R., & Kincade, P. W. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.1.257 · Cited by 247
Lin, Y.-H., & Yang-Yen, H.-F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105132200 · Cited by 246
The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells
Lu, C., Redd, P. S., Lee, J. R., Savage, N., & Liu, K. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1247135 · Cited by 230
Self-citationDefining and Understanding Adaptive Resistance in Cancer Immunotherapy
Kim, T. K., Herbst, R. S., & Chen, L. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.05.001 · Cited by 192
Taylor, A., Harker, J. A., Chanthong, K., Stevenson, P. G., Zuniga, E. I., & Rudd, C. E. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.018 · Cited by 190
CD44 Regulates Survival and Memory Development in Th1 Cells
Baaten, B. J. G., Li, C.-R., Deiro, M. F., Lin, M. M., Linton, P. J., & Bradley, L. M. (2010) · Immunity · doi:10.1016/j.immuni.2009.10.011 · Cited by 183
IRF8 Regulates Transcription of Naips for NLRC4 Inflammasome Activation
Karki, R., Lee, E., Place, D., Samir, P., Mavuluri, J., Sharma, B. R., Balakrishnan, A., Malireddi, R. K. S., Geiger, R., Zhu, Q., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.055 · Cited by 180
Curtsinger, J. M., Lins, D. C., & Mescher, M. F. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.7.3236 · Cited by 177
Kurotaki, D., Yamamoto, M., Nishiyama, A., Uno, K., Ban, T., Ichino, M., Sasaki, H., Matsunaga, S., Yoshinari, M., Ryo, A., et al. (2014) · Nature Communications · doi:10.1038/ncomms5978 · Cited by 176
Self-citationThe BXH2 mutation in IRF8 differentially impairs dendritic cell subset development in the mouse
Tailor, P., Tamura, T., Morse, H. C., & Ozato, K. (2008) · Blood · doi:10.1182/blood-2007-07-100750 · Cited by 176
Self-citationLuda, K. M., Joeris, T., Persson, E. K., Rivollier, A., Demiri, M., Sitnik, K., Pool, L., Holm, J. B., Melo-González, F., Richter, L., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.008 · Cited by 171
Yoshida, Y., Yoshimi, R., Yoshii, H., Kim, D., Dey, A., Xiong, H., Munasinghe, J., Yazawa, I., O'Donovan, M. J., Maximova, O. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2013.11.022 · Cited by 164
Self-citationBecker, A. M., Michael, D. G., Satpathy, A. T., Sciammas, R., Singh, H., & Bhattacharya, D. (2012) · Blood · doi:10.1182/blood-2011-06-364976 · Cited by 157
Transcription factor IRF8 directs a silencing programme for TH17 cell differentiation
Ouyang, X., Zhang, R., Yang, J., Li, Q., Qin, L., Zhu, C. Y., Liu, J., Ning, H., Shin, M. S., Gupta, M., et al. (2011) · Nature Communications · doi:10.1038/ncomms1311 · Cited by 144
Self-citationMarisa, L., Svrcek, M., Collura, A., Becht, É., Cervera, P., Wanherdrick, K., Buhard, O., Goloudina, A. R., Jonchère, V., Sèlves, J., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx136 · Cited by 143
Identification of target genes and a unique cis element regulated by IRF-8 in developing macrophages
Tamura, T., Thotakura, P., Tanaka, T. S., Ko, M. S. H., & Ozato, K. (2005) · Blood · doi:10.1182/blood-2005-01-0080 · Cited by 142
Self-citationLee, J., Zhou, Y. J., Ma, W., Zhang, W., Aljoufi, A., Luh, T., Lucero, K., Liang, D., Thomsen, M., Bhagat, G., et al. (2017) · Nature Immunology · doi:10.1038/ni.3789 · Cited by 140
Self-citationTranscription Factor IRF8 Orchestrates the Adaptive Natural Killer Cell Response
Adams, N. M., Lau, C. M., Fan, X., Rapp, M., Geary, C. D., Weizman, O.-E., Díaz-Salazar, C., & Sun, J. C.-Y. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.018 · Cited by 138
Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade
Ariyan, C. E., Brady, M. S., Siegelbaum, R. H., Hu, J., Bello, D. M., Rand, J. G., Fisher, C., Lefkowitz, R. A., Panageas, K. S., Pulitzer, M. P., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0356 · Cited by 134
CD8 T-cell recognition of acquired alloantigen promotes acute allograft rejection
Harper, S., Ali, J. M., Wlodek, E., Negus, M. C., Harper, I. G., Chhabra, M., Qureshi, M. S., Hoff, M., Bolton, E. M., Bradley, J. A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513533112 · Cited by 117
Biallelic mutations in IRF8 impair human NK cell maturation and function
Mace, E. M., Bigley, V., Gunesch, J. T., Chinn, I. K., Angelo, L. S., Care, M. A., Maisuria, S., Keller, M. D., Togi, S., Watkin, L. B., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86276 · Cited by 112
Self-citationNagato, T., Lee, Y.-R., Harabuchi, Y., & Celis, E. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2781 · Cited by 103
Self-citationMiyagawa, F., Zhang, H., Terunuma, A., Ozato, K., Tagaya, Y., & Katz, S. I. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201453109 · Cited by 102
Self-citationYang, D., Thangaraju, M., Greeneltch, K. M., Browning, D. D., Schoenlein, P. V., Tamura, T., Ozato, K., Ganapathy, V., Abrams, S. I., & Liu, K. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4068 · Cited by 99
Self-citationIFN Regulatory Factor 8 Restricts the Size of the Marginal Zone and Follicular B Cell Pools
Feng, J., Wang, H., Shin, D., Masiuk, M., Qi, C., & Morse, H. C. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001950 · Cited by 88
Netherby, C. S., Messmer, M. N., Burkard-Mandel, L. E., Colligan, S. H., Miller, A., Gomez, E. C., Wang, J., Nemeth, M. J., & Abrams, S. I. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601722 · Cited by 83
Self-citationLee, K. Y., Geng, H., Ng, K. M., Yu, J. Q., van Hasselt, A., Cao, Y., Zeng, Y.-X., Wong, A., Wang, X., Ying, J., et al. (2008) · Oncogene · doi:10.1038/onc.2008.147 · Cited by 79
Wang, H., Yan, M., Sun, J., Jain, S., Yoshimi, R., Abolfath, S. M., Ozato, K., Coleman, W. G., Ng, A. P., Metcalf, D., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301939 · Cited by 78
Self-citationThaker, Y. R., Schneider, H., & Rudd, C. E. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.10.020 · Cited by 69
IRF8‐dependent Molecular Complexes Control the Th9 Transcriptional Program
Humblin, E., Thibaudin, M., Chalmin, F., Derangère, V., Limagne, E., Richard, C., Flavell, R. A., Chevrier, S., Ladoire, S., Berger, H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01070-w · Cited by 67
McGough, J. M., Yang, D., Huang, S., Georgi, D. E., Hewitt, S. M., Röcken, C., Tänzer, M., Ebert, M. P., & Liu, K. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0280 · Cited by 62
Self-citationTranscription factor IRF8 controls Th1-like regulatory T-cell function
Lee, W., Kim, H. S., Baek, S. Y., & Lee, G. R. (2015) · Cellular and Molecular Immunology · doi:10.1038/cmi.2015.72 · Cited by 58
NFATc3 regulates the transcription of genes involved in T-cell activation and angiogenesis
Urso, K., Alfranca, A., Martínez-Martínez, S., Escolano, A., Ortega‐Pérez, I., Rodríguez, A., & Redondo, J. M. (2011) · Blood · doi:10.1182/blood-2010-12-322701 · Cited by 56
Kim, S.-H., Burton, J. H., Yu, C., Sun, L., He, C., Wang, H., Morse, H. C., & Egwuagu, C. E. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500653 · Cited by 29
Li, W., Nagineni, C. N., Ge, H., Efiok, B. J. S., Chepelinsky, A. B., & Egwuagu, C. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.14.9686 · Cited by 28
Two Strings in One Bow: PD-1 Negatively Regulates via Co-receptor CD28 on T Cells
Krueger, J., & Rudd, C. E. (2017) · Immunity · doi:10.1016/j.immuni.2017.04.003 · Cited by 26
Yan, M., Wang, H., Sun, J., Liao, W., Li, P., Zhu, Y., Xu, C., Joo, J., Sun, Y., Abbasi, S., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1500766 · Cited by 23
Miyagawa, F., Tagaya, Y., Kim, B., Patel, H. J., Ishida, K., Ohteki, T., Waldmann, T. A., & Katz, S. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.2.1109 · Cited by 20
Sun, L., Leger, A. J. S., Yu, C., He, C., Mahdi, R. M., Chan, C., Wang, H., Morse, H. C., & Egwuagu, C. E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155420 · Cited by 20
Th17 cell differentiation proceeds independently of IRF8
Newman, D. M., Leung, P. S., Putoczki, T. L., Nutt, S. L., & Cretney, E. (2016) · Immunology and Cell Biology · doi:10.1038/icb.2016.33 · Cited by 8
Cited by
Yuan, Z., Li, Y., Zhang, S., Wang, X., Dou, H., Yu, X., Zhang, Z., Yang, S., & Xiao, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01744-8 · Cited by 977
Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer
Lee, H.-O., Hong, Y., Etlioglu, H. E., Cho, Y. B., Pomella, V., Van den Bosch, B., Vanhecke, J., Verbandt, S., Hong, H., Min, J.-W., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0636-z · Cited by 910
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
Bi, K., He, M. X., Bakouny, Z., Kanodia, A., Napolitano, S., Wu, J., Grimaldi, G., Braun, D. A., Cuoco, M. S., Mayorga, A., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.02.015 · Cited by 618
Progressive immune dysfunction with advancing disease stage in renal cell carcinoma
Braun, D. A., Street, K., Burke, K. P., Cookmeyer, D. L., Denize, T., Pedersen, C. B., Gohil, S. H., Schindler, N., Pomerance, L., Hirsch, L., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.02.013 · Cited by 504
CD44: A Multifunctional Mediator of Cancer Progression
Hassn Mesrati, M., Syafruddin, S. E., Mohtar, M. A., & Syahir, A. (2021) · Biomolecules · doi:10.3390/biom11121850 · Cited by 492
Metadata
- Authors
- Klement, J. D., Paschall, A. V., Redd, P. S., Ibrahim, M. L., Lu, C., Yang, D., Celis, E., Abrams, S. I., Ozato, K., & Liu, K.
- Venue
- Journal of Clinical Investigation
- Published
- 2018-11-05
- Volume
- 128
- Issue
- 12
- Pages
- 5549-5560
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2898701133
- Cited by
- 368
- References
- 67
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.